- Home
- RMMZ vs ZNTL Comparison
RMMZ vs ZNTL Comparison
Compare RMMZ & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMMZ
- ZNTL
- Stock Information
- Founded
- RMMZ 2022
- ZNTL 2014
- Country
- RMMZ United States
- ZNTL United States
- Employees
- RMMZ N/A
- ZNTL N/A
- Industry
- RMMZ Investment Managers
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- RMMZ Finance
- ZNTL Health Care
- Exchange
- RMMZ Nasdaq
- ZNTL Nasdaq
- Market Cap
- RMMZ 133.6M
- ZNTL 102.2M
- IPO Year
- RMMZ N/A
- ZNTL 2020
- Fundamental
- Price
- RMMZ $14.39
- ZNTL $1.26
- Analyst Decision
- RMMZ
- ZNTL Buy
- Analyst Count
- RMMZ 0
- ZNTL 8
- Target Price
- RMMZ N/A
- ZNTL $8.53
- AVG Volume (30 Days)
- RMMZ 25.6K
- ZNTL 761.8K
- Earning Date
- RMMZ 01-01-0001
- ZNTL 05-20-2025
- Dividend Yield
- RMMZ 7.33%
- ZNTL N/A
- EPS Growth
- RMMZ N/A
- ZNTL N/A
- EPS
- RMMZ 0.82
- ZNTL N/A
- Revenue
- RMMZ N/A
- ZNTL $67,425,000.00
- Revenue This Year
- RMMZ N/A
- ZNTL N/A
- Revenue Next Year
- RMMZ N/A
- ZNTL N/A
- P/E Ratio
- RMMZ $19.41
- ZNTL N/A
- Revenue Growth
- RMMZ N/A
- ZNTL N/A
- 52 Week Low
- RMMZ $12.92
- ZNTL $1.01
- 52 Week High
- RMMZ $16.99
- ZNTL $13.24
- Technical
- Relative Strength Index (RSI)
- RMMZ 46.40
- ZNTL 39.62
- Support Level
- RMMZ $14.20
- ZNTL $1.20
- Resistance Level
- RMMZ $14.57
- ZNTL $1.51
- Average True Range (ATR)
- RMMZ 0.14
- ZNTL 0.10
- MACD
- RMMZ 0.08
- ZNTL 0.00
- Stochastic Oscillator
- RMMZ 75.00
- ZNTL 16.21
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.